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Bronchial asthmaAbstract Background: Asthma is a major public health problem with a high economic burden. It
involves several inﬂammatory cells and multiple mediators. Granzyme B is an inﬂammatory medi-
ator expressed and secreted by both immune and non immune cells. Recently it was found to play a
role in the pathogenesis of asthma.
The aim of this work: was to evaluate the effect of both inhaled and oral corticosteroids on spu-
tum granzyme B in asthmatic patients with moderate severity.
Methods: The study included 25 patients with moderate persistent asthma plus 15 healthy sub-
jects as a control group. Granzyme B was measured before treatment with corticosteroids then after
inhalation therapy and oral therapy.
Results: It was found that expected pulmonary function parameters were signiﬁcantly lower in
asthmatic patients than in controls. Sputum granzyme B levels were signiﬁcantly higher in asthmatic
patients than in controls. Sputum granzyme B levels were signiﬁcantly lower after treatment with
inhaled corticosteroids than basal levels. Oral corticosteroids further signiﬁcantly lowered granzyme
B, but the lowering effect of inhaled steroids was signiﬁcantly higher than that of oral drugs. There
was no statistically signiﬁcant correlation between granzyme B and PFTs in asthmatic patients.
Conclusion: Granzyme B levels are elevated in bronchial asthma. Granzyme B could play a role
in the pathogenesis of bronchial asthma. Both inhaled and oral corticosteroids lowered granzyme B
levels signiﬁcantly. The lowering effect of inhaled corticosteroids on sputum granzyme B is more
than that of the oral corticosteroids.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.
Table 2 Sex distribution among patients and controls.
Sex Patients Controls Total
Female N 14 6 20
% 56.00 40.00 50.00
Male N 11 9 20
% 44.00 60.00 50.00
Total N 25 15 40
% 100.00 100.00 100.00
Chi-square X2 0.965
P-value 0.326
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Granzymes are recently discovered inﬂammatory mediators
claimed to play a role in asthma. Granzyme B is sorted to a
granule compartment that can be mobilized in a way similar
to histamine. Thus Granzyme B must be considered as a
potential mediator in asthma [5]. Granzyme B is a multifunc-
tional protease that may have important role in a number of
inﬂammations. It can be expressed and secreted by both
immune and non immune cells, so granzyme B may have a lar-
ger role in chronic inﬂammation, auto immune and degenera-
tive diseases than previously believed [17]. Granzyme B may
play important role in the pathogenesis of asthma, so reduc-
tion in Granzyme B expression can inhibit the apoptosis of air-
way epithelial cells and tissue remodeling [18]. Induced sputum
provides a non invasive tool for investigating mediators in var-
ious asthma subtypes. Sputum induction is performed by inha-
lation of hypertonic saline (NaCl 4.5%) or isotonic saline
solution (NaCl 0.9%) 15 min after pre-medication with 400
microgram of inhaled salbutamol [6].
Subjects and methods
In this cross sectional prospective case-control study, 25
patients (14 females and 11 males) with moderate persistent
asthma of those attending the Chest Department at Benha
University Hospitals were included. The study was conducted
between May 2012 and September 2013.15 healthy subjects
were included as a control group.
Exclusion criteria
1. Patients received oral or inhaled corticosteroids in the pre-
ceding 2 weeks.
2. Patients on other immune suppressant or anti-inﬂamma-
tory therapy.
3. Patients with renal or hepatic impairment.
4. Patients with systemic or cardiovascular diseases that may
result in the elevation of Gr B.
Patients were submitted to the following
1. Full history taking.
2. Full clinical examination both general and local.
3. Body mass index (BMI) was calculated as the weight in kg
divided by the height in square meter (kg/m2).
4. Radiological examination: Plain postero anterior chest
X-ray was done to exclude any chest lesion if present.
5. Pulmonary function tests (spirometry) before and after
bronchodilatation.Table 1 Age distribution among patients and controls.
Groups Age
Range Mean ± SD
Patients 19.000–61.000 46.960 ± 11.066
Controls 28.000–66.000 47.200 ± 10.798
There was no statistically signiﬁcant difference between patients and conVentilatory function tests were performed using a Sensor-med-
ics V max series, 2130 spirometer, V6200 Autobox, 6200DL.
Measurement of granzyme B level in sputum
Basal levels of GrB were measured at the start then patients
were given high dose of inhaled steroid in the form of
Budesonide 800 lg (Miﬂonide, caps, 400 mg, Novartis) twice
daily for 2 weeks then low dose of oral steroid in the form of
prednisolone 10 mg (2 tablets/day) for another 2 weeks.
Granzyme B was measured again after 2 weeks of
inhalation therapy and at the end of oral therapy. Granzyme
B was measured by an ELISA assay using a Human Granzyme
B ELISA Kit by Wuhan EIAab Science Co., Ltd.
(www.eiaab.com). Levels of granzyme B were estimated in
pg/ml.
Sputum processing
Sputum was processed within 2 h of collection. Sputum plugs
were harvested and processed with 4· weight/volume of
0.1% dithiothreitol in phosphate buffered saline (PBS).
Samples were ﬁltered through 48 mm mesh and centrifuged
at 1200 rpm for 5 min. to remove cells. Supernatants were
stored at 80 C until ELISA test [13].
Results
Table 2 shows a non statistically signiﬁcant difference between
patients and controls as regards sex distribution.
Table 3 shows a non statistically signiﬁcant difference
between patients and controls as regards BMI.
Table 4 shows a non statistically signiﬁcant difference in
FVC% between patients and controls.
Table 5 shows that FEV1% of the control group is signiﬁ-
cantly higher than the asthmatic group.
Table 6 shows that FEV1/FVC% is signiﬁcantly higher in
the control group than the asthmatic group.T-test
t P-value Sig.
0.067 0.947 NS
trols as regards their age.
Table 3 Distribution of BMI among patients and controls.
Groups BMI T-test
Range Mean ± SD t P-value Sig.
Patients 22.300–62.600 29.332 ± 7.941 0.925 0.361 NS
Controls 23.600–31.200 27.380 ± 2.297
Table 4 Comparison of FVC% predicted between patients and controls.
Groups FVC% T-test
Range Mean ± SD t P-value Sig.
Patients 74.400–112.600 86.556 ± 10.644 0.048 0.962 NS
Controls 80.400–99.000 86.413 ± 5.224
Table 5 Comparison of FEV1% predicted between patients and controls.
Groups FEV1% T-test
Range Mean ± SD t P-value Sig.
Patients 60.000–79.300 65.700 ± 5.925 11.231 <0.001* S
Controls 81.400–104.100 89.827 ± 7.567
Table 6 Comparison of FEV1/FVC% ratio between patients and control.
Groups FEV1/FVC% T-test
Range Mean ± SD t P-value Sig.
Patients 50.660–69.630 62.247 ± 6.826 11.813 <0.001* S
Controls 79.450–95.860 85.979 ± 4.777
Table 7 Comparison of FEF 25–75% between patients and controls.
Groups FEF 25–75% T-test
Range Mean ± SD t P-value Sig.
Patients 31.200–56.800 41.440 ± 7.415 13.727 <0.001* S
Controls 66.000–110.400 85.787 ± 13.090
Table 8 Comparison of granzyme B levels in pg/ml between asthmatic patients and controls.
Groups Granzyme B Level in sputum (before): T-test
Range Mean ± SD t P-value Sig.
Patients 162.700–809.800 392.076 ± 125.690 5.580 <0.001* S
Controls 104.400–292.300 201.560 ± 50.815
Table 9 Comparison of granzyme B levels in pg/ml between males and females before and after inhaled corticosteroids (ICS): and
after oral corticosteroids (OCS).
Granzyme B Level in sputum Female Male T-test
Mean ± SD Mean ± SD t P-value Sig.
Before ICS 428.036 ± 134.485 346.309 ± 101.433 1.673 0.108 NS
After ICS 275.350 ± 71.213 249.291 ± 85.638 0.831 0.414 NS
After OCS 182.957 ± 73.977 173.409 ± 57.575 0.352 0.728 NS
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Table 10 Comparison of granzyme B levels in asthmatic patients in pg/ml before and after inhaled corticosteroids (ICS): and oral
corticosteroids (OCS).
Descriptive Statistics Granzyme B Level in sputum Diﬀerence Paired t-test
Range Mean ± SD Mean SD t P-value
Before ICS 162.700–809.800 392.076 ± 125.690 t1 128.192 136.212 4.706 <0.001*
After ICS 117.700–440.500 263.884 ± 77.311 t2 213.320 147.621 7.225 <0.001*
After OCS 50.200–312.200 178.756 ± 66.098 t3 85.128 87.355 4.873 <0.001*
t1: change between before and after ICS. t2: change between before and after OCS. t3: change between after ICS and after OCS.* signiﬁcant.
Table 11 Correlation between granzyme B and each of age
and BMI, in asthmatic patients and the control group.
Basal granzyme B Level in sputum
R P-value Sig.
Age 0.237 0.254 NS
BMI 0.047 0.824 NS
There was no statistically signiﬁcant correlation between granzyme
B and both of age and BMI, in asthmatic patients and controls.
10 W.K. Shoeib et al.Table 7 shows a signiﬁcantly higher FEF 25–75% in the
control group than the asthmatic group.
Table 8 shows a signiﬁcantly higher granzyme B levels in
asthmatic patients than controls.
Table 9 shows a non statistically signiﬁcant difference in
granzyme B levels between males and females before and after
treatment with corticosteroids.
Table 10 shows that granzyme B levels were signiﬁcantly
lower after treatment with inhaled corticosteroids. Oral ste-
roids further signiﬁcantly lowered granzyme B levels, but the
lowering effect of inhaled steroids was signiﬁcantly higher than
that of oral drugs.
Discussion
The present study aimed to measure the sputum level of gran-
zyme B of asthmatic patients with inhaled and oral corticoste-
roids treatment compared to those of healthy controls There
was no statistically signiﬁcant difference between patients
and controls as regards age (Table 1) and sex (Table 2). Male
sex is a risk factor for asthma in children. Prior to the age of
fourteen, the prevalence of asthma is nearly twice as great in
boys as in girls. As children get older the difference between
the sexes narrows, and by adulthood the prevalence of asthma
is greater in women than in men ([10]). Absence of a signiﬁcant
difference between males and females in our asthmatic patients
is related to the small number of the sample and the age range
(as sex difference is more evident with extreme of age). The
reasons for sex-related difference in asthmatic prevalence are
not clear. However, lung size is smaller in males than in
females at birth but larger in adulthood [12]. There was no sta-
tistically signiﬁcant difference between patients and controls as
regards BMI. Although higher incidence of asthma was seen in
obese patients (especially severe forms) [8], the absence of a sig-
niﬁcant difference between our patients and controls is almost
related to the smaller number of the sample studied. Higher
incidence of severe form of asthma in obese patients is related
to certain mediators such as leptins that affect airway function
and increase the likelihood of asthma development [3].
Other mechanisms by which obesity could potentially inﬂu-
ence asthma are thought to be mechanical factors leading to a
decreased functional residual capacity and tidal volume with
less smooth muscle stretch or through inﬂammatory or
immune modiﬁcation, increase in estrogen, or precipitating
gastro-esophageal reﬂux [15].
Majority of asthmatic patients in the study were non smok-
ers only one patient was ex-smoker. Tobacco smoking is asso-
ciated with accelerated decline of lung function in people with
asthma and increase asthma severity, and may render patientsless responsive to treatment with inhaled glucocorticoids, and
reduces the likelihood of asthma being controlled [2].
In this study pre and post bronchodilator spirometry were
done among 25 cases to conﬁrm the diagnosis of asthma. Sta-
tistical comparisons of pulmonary function tests were done
among all studied groups. FEV1% predicted, FEV1/FVC%
and FEF25–75% were signiﬁcantly lower in asthmatic patients
than controls while FVC% was not statistically different
(Tables 5–7) [1].
The results of this study showed a signiﬁcantly higher levels
of Gr B in asthmatic patients (392.076 ± 125.690 pg/ml) than
controls (201.560 ± 50.815 pg/ml) (Table 8). This result is in
agreement with Athanasia et al. [1] who found that Gr B levels
were signiﬁcantly increased in moderate persistent asthma
compared to mild asthmatics. The study was done on 10
patients with moderate persistent asthma compared to 10
patients with mild asthma to investigate granzyme B levels in
induced sputum, it was 325.6 ± 44 versus 253 ± 24 pg/ml.
Also Sandra et al. [14] found that granzyme B levels were
increased in patients with non eosinophilic asthma (NEA)
(n= 6) and in patients with mixed EA/NEA (n= 8) versus
controls (n= 9) but granzyme B levels in EA (n= 7) were
not signiﬁcantly different from controls.
Results of Sandra et al. [14] indicate that granzyme B is
more important in non allergic asthma, however Khoa et al.
[11] found increased granzyme B and perforin expression in
allergic asthmatic CD4 + i NKT cells compared to healthy
controls and allergic asthma. Sandra et al. [14] showed
increased Gr B levels in BAL from a topic asthmatic follow-
ing segmental allergen provocation and concluded that it is
possible to play a role in the pathogenesis of the disease as
they found increased expression in T-lymphocytes, a result
similar to that of Khoa et al. [11]. Also, Tschopp et al [16]
showed induced production of Gr B, IL 13 and Leukotriene
C4 by blood basophils following allergen sensitization in asth-
matic patients. In the present study Gr B levels were signiﬁ-
cantly lower following inhaled steroids (263.884 ± 77.311)
Table 12 Correlation between granzyme B and PFTs in
asthmatic patients.
Basal granzyme B Level in sputum
R P-value Sig.
FVC% 0.103 0.624 NS
FEV1/FVC 0.142 0.497 NS
FEV1% 0.096 0.649 NS
change in FEV1% 0.099 0.638 NS
FEF25–75% 0.216 0.300 NS
There was no statistically signiﬁcant correlation between granzyme
B and PFTs in asthmatic patients.
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reduction was seen after oral steroids (178.756 ± 66.098),
Table 10. Our result is in agreement with Chiara et al. [4]
who found that methylprednisolone-treated normal NK cells
display reduced levels of intracytoplasmic granzyme B that
was done on 10 patients receiving methylprednisolone. In
the present study there was no statistically signiﬁcant correla-
tion found between granzyme B and pulmonary function tests
(FEV1%, FVC%, FEV1/FVC, FEF25–75%) in asthmatic
patients.(Table 12).This result is in agreement with Hodge
et al. [9] who found that there was no correlation between
sputum granzyme B levels and airﬂow obstruction. Also
Khoa et al. [11], did not ﬁnd any signiﬁcant correlation
between granzyme B levels and forced expiratory volume in
1 s (FEV1).
The study showed that there was no statistically signiﬁcant
correlation between granzyme B and both age and BMI in
asthmatic patients and controls. This result is in agreement
with Hodge et al. [11] who found that there was no correlation
between granzyme B levels and clinical parameters of asthma
such as patient age, disease duration and age of onset. How-
ever, Hala et al. [7] found that granzyme B levels positively
correlate with measures of obesity and insulin resistance and
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